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Abstract
CD8+ T cells identify and kill infected cells through the specific recognition of short viral antigens bound to human major
histocompatibility complex (HLA) class I molecules. The colossal number of polymorphisms in HLA molecules makes it
essential to characterize the antigen-presenting properties common to large HLA families or supertypes. In this context, the
HLA-B*27 family comprising at least 100 different alleles, some of them widely distributed in the human population, is
involved in the cellular immune response against pathogens and also associated to autoimmune spondyloarthritis being
thus a relevant target of study. To this end, HLA binding assays performed using nine HLA-B*2705-restricted ligands
endogenously processed and presented in virus-infected cells revealed a common minimal peptide motif for efficient
binding to the HLA-B*27 family. The motif was independently confirmed using four unrelated peptides. This experimental
approach, which could be easily transferred to other HLA class I families and supertypes, has implications for the validation
of new bioinformatics tools in the functional clustering of HLA molecules, for the identification of antiviral cytotoxic T
lymphocyte responses, and for future vaccine development.
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Introduction
The proteolytic degradation of newly synthesized pathogen
proteins in the cytosol through the combined actions of
proteasomes and different peptidases continuously generates
peptides of typically 8 to 11 residues long, and these fragments
were translocated to the endoplasmic reticulum (ER) lumen
through a transporter associated with antigen-processing (TAP)
molecules. These short peptides are subsequently assembled with
nascent human leukocyte antigen (HLA) class I heavy chain and
b2-microglobulin molecules [1]. This assembly likely occurs
through the interaction of the lateral chains of anchor residues
at position 2 (P2) and the C-terminus (PV) of the antigenic peptide
[2,3], and these chains are inserted deeply into specific pockets of
the antigen recognition groove of the HLA class I molecule [4,5].
The stable HLA/peptide complexes are eventually exported to the
cell membrane and presented for cytotoxic T lymphocyte (CTL)
recognition [6]. The detection of pathogen peptides by specific T
cell receptors results in the killing of pathogen-infected cells.
HLA class I is the largest polymorphic biological system
described. More than 7,000 HLA class I alleles have been
identified to date (Immuno Polymorphism Database, http://www.
ebi.ac.uk/ipd), and classic HLA serologies have been largely
divided into complex HLA gene families with increasing numbers
of expressed protein subtypes. For example, to date, HLA-B*27 (a
well-studied HLA class I family) comprises at least 100 different
alleles. Although the presence of Arg at P2 is necessary for HLA-
B*27 ligands (SYFPEITHI Database [3]), only a partial overlap-
ping of the peptide repertoire has been observed in different HLA-
B*27 subtypes [7]. Individual HLA-B*27 subtypes could present
or not specific ArgP2-containing peptides, or the same ligand
could bind to different HLA-B*27 subtypes with a broad range of
affinity values [8]. Thus, the existence of HLA-B*27 ligands with
additional binding motifs for presentation by all or most of the
different HLA-B*27 subtypes remains unknown. To address this
question, the binding affinity of a homogeneous set of nine
naturally processed viral HLA-B*2705 ligands with different
sequences, identified using mass spectrometry analysis of complex
HLA-bound peptide pools isolated from large amounts of Human
respiratory syncytial virus (HRSV)-infected cells [9], was examined
using seven phylogenetically and functionally different major
HLA-B*27 subtypes [10,11]. This analysis revealed a common
minimal peptide motif for efficient binding to different HLA-B*27
subtypes.
Materials and Methods
HLA-B*27 cell lines and antibodies
RMA-S is a TAP-deficient murine cell line that expresses the
mouse H-2b haplotype [12]. Transfected RMA-S cell lines
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expressing HLA-B*2701 [13], -B*2702 [13], -B*2703 [14], -
B*2704 [8], -B*2705 [15], -B*2706 [8], or -B*2709 [16] have been
previously described (summarized in Figure S1). All cell lines were
cultured in RPMI 1640 medium supplemented with 10% heat-
inactivated fetal bovine serum and 50 mM b-mercaptoethanol.
ME1, a monoclonal antibody (mAb) specific for HLA-B27, -B7,
and -Bw22 [17] and goat anti-mouse IgG-FITC (AbD Serotec,
Kidlington, UK) were used in this study.
Synthetic peptides
The peptides were synthesized in a peptide synthesizer (model
433A; Applied Biosystems, Foster City, CA) and subsequently
purified through reversed-phase HPLC. The molecular mass of
the peptides was established using MALDI-TOF MS, and the
peptide composition was determined through mLC-MS/MS.
HLA/Peptide Stability Assays
The synthetic peptide CMV pp65294-302 (VAFTSHEHF, HLA-
C*012-restricted)[18] was used as a negative control in complex
stability assays. In addition, for some HLA-B*27 subtypes, the Flu
NP peptide (SRYWAIRTR, HLA-B27-restricted) [19] was used as
a positive control. The transfected RMA-S B*27 cell lines were
incubated at 26uC for 16 h to promote the expression of empty
HLA class I molecules (without antigenic peptide) at the cell
membrane, as these molecules are stable at 26uC but not at 37uC.
The cells were washed and incubated for 2 h at 26uC with various
concentrations of peptide in medium without fetal bovine serum.
The cells were maintained at 37uC for an additional 2 h to
facilitate the internalization of empty MHC class I molecules.
Subsequently, the cells were collected for flow cytometry to
discriminate between bound or unbound peptides. MHC expres-
sion was measured using 100 ml of hybridoma culture supernatant
containing the ME1 (anti-HLA-B27) mAb and the secondary
antibody as previously described [20]. The data were acquired
using a FACSCanto flow cytometer (BD Biosciences, San Jose,
CA, USA) and analyzed using BD FACSDiva software version 6
(BD Bioscience). The cells alone exhibited peak fluorescence
intensities similar to the background staining observed with
secondary Ab alone. The fluorescence index was calculated as
the ratio of the mean peak channel fluorescence of the sample to
that of the control incubated without peptide. Peptide binding was
expressed as the EC50, the molar concentration of the peptide at
50% of the maximum fluorescence obtained at a concentration
range of 0.01–200 mM.
Statistical analysis
Unpaired Student’s t test was used to analyze statistical
significance. P values,0.05 were considered significant.
Results
HRSV specific ligands bind to the B*2705 molecule with a
broad range of affinities
Nine HLA-B*2705-restricted ligands endogenously processed
and presented in the HRSV-infected cells were previously
identified (Table S1) [9]. To confirm that HLA-B*2705 is the
Major Histocompatibility Complex (MHC) class I molecule
responsible for the presentation of these ligands, MHC/peptide
complex stability assays were performed using TAP-deficient
RMA-S cells transfected with the HLA-B*2705 molecule. Four
HRSV synthetic peptides (L 2089-2097, M2 150-159, NP 100-109 and
NP 184-194) showed stable numbers of HLA-peptide surface
complexes similar to those of the well known HLA-B*2705
epitope from influenza virus (Figure 1A and Table 1). For the
Figure 1. HLA-B*2705 stabilization with synthetic HRSV ligands. The stability of HLA-B*2705/peptide complexes on the cell surface of
transfected RMA-S cells was measured through flow cytometry. Panel A: The indicated peptides were used at 200 mM. The CMV pp65 and Flu NP
peptides were used as negative and positive controls, respectively. The mAb ME1 was used for staining. The results, calculated as fluorescence
indexes, show the means 6 SD of 4-5 independent experiments. Significant P values (***, p,0.001; **, p,0.01; *, p,0.05) versus negative or positive
peptide controls are represented as white or black asterisks, respectively. Panel B: The titration curves for the indicated synthetic peptides with HLA-
B*2705 are depicted. The results show the mean values obtained from three or four independent experiments. The calculated EC50 values (mM)
(means 6 SD) are shown in the legend of panel B. A representative experiment is depicted in panel C.
doi:10.1371/journal.pone.0106772.g001
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other five HRSV synthetic peptides (M 76-84, M 169-177, NP 195-205,
NS2 37-45 and P 198-208), the induction of HLA-peptide surface
complexes was somewhat lower than that of the positive control
(Figure 1A and Table 1). In addition, the relative MHC class I
affinity was determined for all HRSV peptides, according to the
EC50 value. The peptides bound to HLA-B*2705 class I molecules
at a broad range of EC50 values commonly observed among
natural ligands: high (M 76-84, M2 150-159, NP 184-194, NP 195-205
and NS2 37-45), medium (L 2089-2097, and NP 100-109) or low affinity
(M 169-177 and P 198-208) (Figure 1B and Table 2). A representative
experiment is shown in Figure 1C. These data confirm that all
ligands detected in HRSV-infected cells were endogenously
presented in association with the B*2705 molecule.
The His59Tyr change in the A pocket induces a moderate
decrease in the binding of HRSV-specific ligands to HLA-
B*27
The B*2703 molecule differs from the prototypical subtype
HLA-B*2705, reflecting a single amino acid change at heavy-
chain residue 59, which is responsible for anchoring the N-
terminus of the peptide within the A pocket of the class I molecule
(Figure S1). The analysis of MHC/peptide complex stability assays
using RMA-S cells transfected with the HLA-B*2703 molecule
showed either no effect (M 76-84, NP 195-205 and NS2 37-45) for
three HRSV synthetic peptides or a moderate decrease in the
EC50 value (L 2089-2097, M 169-177, M2 150-159, NP 100-109, NP 184-
194 and P 198-208) for six HRSV synthetic peptides in response to
the His59Tyr change (Figure 2 and Tables 1 and 2).
Basic, but not nonpolar, C-terminal residues reduce
binding to the B*2704 molecule of viral B*2705-restricted
ligands
In the binding groove, the B*2704 subtype differs from the
B*2705 molecule, reflecting two amino acid changes at residues 77
(Asp to Ser) and 152 (Val to Glu) located in the F and E pockets,
respectively (Figure S1). The analysis of peptide binding to HLA-
B*2704 in transfected RMA-S cells showed almost no effect with
the five HRSV synthetic peptides harboring nonpolar amino acids
at the PV residue (M 76-84, M 169-177, NP 100-109, NP 184-194, and
NP 195-205; Tables 1 and 2, and Figure 3) compared with HLA-
B*2705 affinity. In contrast, according to the B*2704-EC50, three
HRSV ligands with basic PV residues showed a moderately
decreased affinity to B*2704 compared with B*2705 (L 2089-2097,
M2 150-159, and NS2 37-45). Moreover, P 198-208, the low affinity
ligand for the B*2705 molecule, did not bind to the B*2704
subtype (Figure 3 and Tables 1 and 2).
HRSV B*2705-restricted ligands with nonpolar PV
residues exhibit high-affinity binding to B*2706
B*2704 and B*2706 differ at two amino acids, His114Asp and
Asp116Tyr, located in the same strand of the b-pleated sheet floor
of the peptide binding site of HLA-B*27 (Figure S1). These
changes highly stabilized (in the range of mM) the binding of the
five HRSV ligands harboring nonpolar PV residues (M 76-84, M
169-177, NP 100-109, NP 184-194, and NP 195-205) to B*2706 (Figure 4
and Tables 1 and 2). In contrast, a moderate increase (NS2 37-45
and P 198-208) or decrease (L 2089-2097, and M2 150-159) in affinity to
Figure 2. HLA-B*2703 stabilization with synthetic HRSV ligands. The stability of HLA-B*2703/peptide complexes on the cell surface of
transfected RMA-S cells was measured using flow cytometry. The results shown in left and right panels are depicted as in Fig. 1A and 2B, respectively,
showing the mean values obtained from three or four independent experiments.
doi:10.1371/journal.pone.0106772.g002
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Figure 3. HLA-B*2704 stabilization with synthetic HRSV ligands. The stability of HLA-B*2704/peptide complexes on the cell surface of
transfected RMA-S cells was measured through flow cytometry. The results shown in left and right panels are depicted as in Fig. 1A and 2B,
respectively, showing the mean values obtained from three or four independent experiments.
doi:10.1371/journal.pone.0106772.g003
Figure 4. HLA-B*2706 stabilization with synthetic HRSV ligands. The stability of HLA-B*2706/peptide complexes on the cell surface of
transfected RMA-S cells was measured through flow cytometry. The results shown in left and right panels are depicted as in Fig. 1A and 2B,
respectively, showing the mean values obtained from three or four independent experiments.
doi:10.1371/journal.pone.0106772.g004
Anchor Motifs for Efficient HLA-B*27 Binding
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B*2706 was observed for HRSV peptides containing basic amino
acids in the PV residue compared with binding to B*2704. Thus,
nonpolar PV residues could be used as additional strong auxiliary
anchor motifs in B*2706 ligands.
High-affinity binding to B*2709 of viral ligands with
nonpolar PV residues
B*2709 differs from B*2705 by a single amino acid change,
Asp116His, located in a strand of the b-pleated sheet floor of the
peptide binding site of HLA-B*27 (Figure S1). This change
stabilized (M 76-84, NP 184-194, and NP 195-205) or increased (M 169-
177, and NP 100-109) the binding of the five HRSV ligands
harboring nonpolar PV residues to B*2709 compared with
binding to the prototypical subtype B*2705 (Figure 5 and Tables 1
and 2). In contrast, a moderate decrease in affinity was observed
for two HRSV peptides containing basic amino acids in the PV
residue (L 2089-2097, and NS2 37-45) compared with binding to
B*2705, except with M2 150-159 ligand where a basic amino
terminal residue could compensate the loss of interaction in the F
pocket. Thus, nonpolar PV residues are sufficient for efficient
binding to the B*2709 class I molecule.
Nonpolar C-terminal residues in high affinity B*2705-
restricted viral ligands preserve the binding affinity to the
B*2701 molecule
B*2701 differs from B*2705, reflecting three amino acid
changes, Asp74Tyr, Asp77Asn, and Leu81Ala, located in the C/
F cavity of the HLA-B*27 peptide binding site (Figure S1). These
changes destabilized the binding of all HRSV peptides except
those ligands with nonpolar amino acids in the PV residue, which
exhibited high affinity for the B*2705 molecule (M 76-84, NP 184-
194, and NP 195-205) (Figure 6 and Tables 1 and 2). Thus, nonpolar
PV residues are necessary, but not sufficient, for efficient binding
to the B*2701 class I molecule.
Hydrophobic C-terminal residues, such as Leu or Ile,
preserve the binding to the B*2702 molecule of HRSV
B*2705-restricted ligands
The B*2702 subtype differs from the B*2705 molecule,
reflecting three amino acid changes at positions 77 (Asp to Asn),
80 (Thr to Ile) and 81 (Asp to Tyr), located in the F pocket (Figure
S1). Only the two HRSV peptides with Leu/Ile PV residues, M
169-177 and NP 195-205, similarly stabilized the binding to both
B*2705 and B*2702 molecules (Figure 7 and Tables 1 and 2). In
contrast, the binding affinity to B*2702 was moderately decreased
for the NP184-194 peptide, and strongly reduced for the other six
viral ligands (Tables 1 and 2). Thus, hydrophobic PV residues,
such as Leu/Ile, serve as additional auxiliary anchor motifs for
B*2702-binding.
A common minimal motif for ligands of the seven
different HLA-B*27 subtypes
Table 3 summarizes the HLA-B*27-binding patterns of the
different HRSV B*2705-restricted ligands used in this study (Table
S1). Most of the viral ligands bound to various HLA-B*27
subtypes, despite amino acid differences in relevant residues that
contribute to the antigen binding site; however, only two of these
ligands (NP 184-194, and NP 195-205) efficiently bound to all seven
Figure 5. HLA-B*2709 stabilization with synthetic HRSV ligands. The stability of HLA-B*2709/peptide complexes on the cell surface of
transfected RMA-S cells was measured through flow cytometry. The results shown in left and right panels are depicted as in Fig. 1A and 2B,
respectively, showing the mean values obtained from three or four independent experiments.
doi:10.1371/journal.pone.0106772.g005
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HLA-B*27 subtypes studied. Both ligands contain basic amino
acids in the N-terminus and a large and hydrophobic lateral chain
in the C-terminal residues. This structure establishes the Arg/Lys-
Arg-Xn-Ile/Met sequence as the common minimal peptide motif
for efficient binding to seven different HLA-B*27 subtypes. To test
this prediction three different peptides, HIV gp160 500-508 [21],
MV F 438-446 [22], and Influenza virus PB1 238-246 [23], harboring
the identified minimal peptide motif (basic residue at P1 and large
hydrophobic aliphatic residue at PV), were studied. Interestingly,
MHC/peptide complex stability assays showed efficient binding of
these synthetic peptides to all seven HLA-B*27 subtypes tested
(Tables 2 and 3). In addition, a synthetic peptide with only the
common minimal peptide motif (RRAAAAAAAI) efficiently
bound to all seven HLA-B*27 subtypes analyzed (Tables 2 and
3). Conversely, the exchange for Ala of the Met residue at CV
position in both NP 184-194, and NP 195-205 peptides abolished the
interaction with B*2701 subtype (Table 4). Also, this monosubsti-
tution significantly decreased the binding of A11-NP 195-205
peptide to B*2702 subtype (Table 4). Moreover the exchange for
Ala of the Arg residue at P1 position in NP 184-194 peptide
considerably decreased the binding to B*2703 subtype (Table 4).
Compared with the affinity of the nine HRSV ligands for
B*2705, 7 ligands exhibited decreased affinity for B*2701 and
B*2702, 6 ligands showed decreased affinity for B*2703, 4 ligands
showed reduced affinity for B*2704 and B*2706, and only 3
ligands exhibited decreased affinity for B*2709 (summarized in
Table 3). These data do not correlate with either the amino acid
differences between subtypes or the individual interactions in the
respective pockets, indicating compensatory effects of changes in
some residues. These effects were more evident with the B*2706
subtype, showing increased affinity for some HRSV ligands with
nonpolar PV residues compared with the B*2705 subtype. Thus,
based on the affinity patterns with HLA-B*27 subtypes, a
functional relationship between B*2705 and the other subtypes
could be established as B*2705.B*2709.B*2706.B*2704.
B*2703.B*2701 = B*2702.
Discussion
Using large scale mass spectrometry analysis, an extensive
knowledge of HLA-B*2705 ligandome (with approximately 2,000
peptides identified) has been reported [7,24]. In contrast, few
endogenous natural ligands have been identified in other HLA-
B*27 subtypes: 32, 49, 38 and 50 from B*2703, B*2704, B*2706
and B*2709, respectively, and only 8 and 15 from B*2701 and
B*2701, respectively (summarized in [7] and SYFPEITHI
database [3]). Except for the ArgP2 residue, no additional anchor
or auxiliary anchor motifs were identified in these studies. Thus, in
the present study the Arg/Lys-Arg-Xn-Ile/Leu/Met sequence was
identified as the minimal common peptide motif for efficient
binding to the seven major, phylogenetically (Figure S2) and
functionally different HLA-B*27 subtypes [10,11], thereby estab-
lishing the criteria to analyze the influence of the HLA-B*27
polymorphism on pathogen peptide presentation and T cell
epitope predictions for the rational design of vaccines to treat large
HLA families.
Extensive analyses of alloreactive T cell responses from HLA-
B*27-negative individuals against B*2702 [25], B*2703 [10],
Figure 6. HLA-B*2701 stabilization with synthetic HRSV ligands. The stability of HLA-B*2701/peptide complexes on the cell surface of
transfected RMA-S cells was measured through flow cytometry. The results shown in left and right panels are depicted as in Fig. 1A and 2B,
respectively, showing the mean values obtained from three or four independent experiments.
doi:10.1371/journal.pone.0106772.g006
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B*2704 [26], B*2705 [10], and B*2709 [27] subtypes at the clonal
level to assess T cell epitope sharing among HLA-B*27 subtypes
have been previously described. These studies defined the
functional relationship as B*2705.B*2709.B*2703.B*2702.
B*2701.B*2704.B*2706, reflecting amino acid differences
between subtypes. However, in contrast to self-restricted pathogen
recognition in normal cellular immune responses, the allogenic
anti-B*27 CTL clones recognized both polymorphic allo-MHC
residues and self-derived peptides [14]. Thus, the direct contribu-
tion of these polymorphic HLA-B*27 residues to the CTL epitope
could disguise both cross-presenting antigen peptide properties
and the degree of functional relationship between the different
HLA-B*27 subtypes. As the antigen processing and presentation
machinery is similar, if not identical, in all cell lines expressing the
different HLA-B*27 subtypes, the nine HLA-B*2705-restricted
ligands endogenously processed and presented in the HRSV-
infected cells might also be presented by the diverse HLA-B*27
subtypes according to affinity. Thus, the functional relationship
between subtypes established with the HRSV ligands through
affinity assays in the current report could be a better approxima-
tion to determine the antigen peptide-presenting properties of
HLA-B*27 class I molecules, and this information could be
applicable to the rational design of vaccines.
Few studies have analyzed antigen binding and/or presentation
of the same viral ligands to different HLA-B27 subtypes. Four
EBV ligands (EBNA3C 258-266, RRIYDLIEL; EBNA3B 243-253,
RRARSLSAERY; LMP2 236-244, RRRWRRLTV; EBNA3C 343-
351, FRKAQIQGL) in B*2702, B*2704, and B*2705 subtypes
were tested, and only the EBNA3C 258-266 ligand tended to be
immunodominant and was recognized in the context of all three
B27 subtypes studied, whereas the LMP 236-244 ligand was only
recognized associated to B*2704 [28]. In contrast, in another
study, the LMP 236-244 ligand was recognized by one of four CTL
clones in the context of five HLA-B*27 (B*2702, B*2704, B*2705,
B*2706 and B*2709) subtypes analyzed [29]. In addition two
ligands, HIV gag 265-279 (KRWIILGNKIVRMYC) and Flu NP
380-393 (ELRSRYWAIRTRSG), were presented by both B*2702
and B*2705 subtypes [30]. Only one of these six viral epitopes
harbors the minimal peptide motif for the efficient binding
described in the current study, and this peptide was restricted by
the three HLA-B27 subtypes analyzed (B*2702, B*2704 and
B*2705). However, only an endogenous ligand derived from
human histone H3.3 has been previously described for binding to
B*2701 [13], B*2702 [31], B*2703 [32], B*2704 [33], B*2705
[34], B*2706 [33] and B*2709 [16] subtypes. This ligand,
containing the RRYQKSTEL sequence, also harbors a basic
amino acid in the N-terminal residue and a large and hydrophobic
lateral chain in C-terminal residue, consistent with the motif
defined in the present study.
Thus, studies examining different HLA class I families and
supertypes are needed to determine the conserved anchor or
auxiliary motifs common to these HLA clusters and validate new
bioinformatics tools for the functional clustering of MHC
molecules [35]. These data are also relevant for the identification
of antiviral cytotoxic T lymphocyte responses and vaccine
development.
Figure 7. HLA-B*2702 stabilization with synthetic HRSV ligands. The stability of HLA-B*2702/peptide complexes on the cell surface of
transfected RMA-S cells was measured through flow cytometry. The results shown in left and right panels are depicted as in Fig. 1A and 2B,
respectively, showing the mean values obtained from three or four independent experiments.
doi:10.1371/journal.pone.0106772.g007
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